Vycor Medical, Inc. (OTCQB: VYCO) has reported a substantial increase in revenue and operating profit for the three and six months ended June 30, 2025, highlighting the company's growth trajectory and its strategic focus on international markets. The Vycor Medical division, known for its ViewSite™ Brain Access System (VBAS), saw revenues increase by 24% and 28% for the three and six months ended June 30, 2025, respectively, compared to the same periods in 2024. This growth is largely attributed to the company's expansion into new international markets, including France and Spain, through new distribution agreements.
The company's operating profit also saw significant improvements, with non-GAAP operating profit reaching $84,481 and $106,944 for the three and six months ended June 30, 2025, respectively. These figures represent a substantial increase over the 2024 periods, underscoring the company's operational efficiency and the growing demand for its neurosurgical and vision rehabilitation solutions.
In addition to financial growth, Vycor Medical has made strides in clinical research, with two new clinical papers on the VBAS system published in the second quarter of 2025, bringing the total number of peer-reviewed clinical papers to 48. These studies further validate the clinical advantages of the VBAS system in brain surgery and neuro-oncology surgery. Similarly, a new study on NovaVision’s NeuroEyeCoach program demonstrated its effectiveness in improving patients' visual capabilities, whether used in clinical settings or accessed remotely, aligning with global healthcare trends towards digital and home-based therapies.
For more detailed information on Vycor Medical's financial results and its innovative medical solutions, visit https://www.vycormedical.com and https://www.vycorvbas.com.
